C07C61/06

COCRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
20240207229 · 2024-06-27 ·

Provided herein are cocrystalline forms including BTK-I useful in the treatment and prevention of diseases which can be treated with a BTK inhibitor, including BTK-associated diseases and disorders, characterizations, and methods of making these cocrystalline forms.

COCRYSTALLINE FORMS OF A BRUTON'S TYROSINE KINASE INHIBITOR
20240207229 · 2024-06-27 ·

Provided herein are cocrystalline forms including BTK-I useful in the treatment and prevention of diseases which can be treated with a BTK inhibitor, including BTK-associated diseases and disorders, characterizations, and methods of making these cocrystalline forms.

PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF
20180186822 · 2018-07-05 ·

The current invention relates to series of co-crystals of platinum analogues and their pharmaceutical use. The co-crystals of the subject invention may be used in the treatment or prevention of cancers and virus infections.

PHARMACEUTICAL CO-CRYSTAL COMPOSITION AND USE THEREOF
20180186822 · 2018-07-05 ·

The current invention relates to series of co-crystals of platinum analogues and their pharmaceutical use. The co-crystals of the subject invention may be used in the treatment or prevention of cancers and virus infections.

Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-()-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-()-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-()-ephedrine from the precipitated salt obtained in step (b).

Processes and Intermediates for Preparing a Macrocyclic Protease Inhibitor of HCV

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-()-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-()-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-()-ephedrine from the precipitated salt obtained in step (b).

Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV

A process for preparing [(1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, by the resolution of racemic 4-oxo-1,2-cyclopentanedicarboxylic acid (V), said process comprising: (a) reacting 4-oxo-1,2-cyclopentanedicarboxylic acid (V) with brucine or (1R,2S)-()-ephedrine, thus preparing the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (V), and (b) precipitating selectively the bis-brucine or bis-(1R,2S)-()-ephedrine salt of (1R,2R)-4-oxo-1,2-cyclopentanedicarboxylic acid II, while the bis-brucine or bis-(1R,2S)-()-ephedrine salt of [(1S,2S)-4-oxo-1,2-cyclopentanedicarboxylic acid stays in solution; (c) liberating the acid II by removal of brucine or (1R,2S)-()-ephedrine from the precipitated salt obtained in step (b).

COMPOUND, LUBRICATING OIL BASE OIL, AND LUBRICATING OIL COMPOSITION
20250207050 · 2025-06-26 · ·

Provided is a compound represented by General Formula (A-1) below. Also provided is lubricant base oil including the compound represented by General Formula (A-1) below. Further provided is a lubricating oil composition including the lubricant base oil. [In General Formula (A-1) above, R.sub.11, R.sub.12, and R.sub.13 are each independently a chained alkyl group having 4 to 30 carbon atoms.] Consequently, a compound, lubricant base oil, and a lubricating oil composition which have low viscosity and a high viscosity index and are excellent in wear resistance and reduction in friction coefficient can be provided.

##STR00001##

COMPOUND, LUBRICATING OIL BASE OIL, AND LUBRICATING OIL COMPOSITION
20250207050 · 2025-06-26 · ·

Provided is a compound represented by General Formula (A-1) below. Also provided is lubricant base oil including the compound represented by General Formula (A-1) below. Further provided is a lubricating oil composition including the lubricant base oil. [In General Formula (A-1) above, R.sub.11, R.sub.12, and R.sub.13 are each independently a chained alkyl group having 4 to 30 carbon atoms.] Consequently, a compound, lubricant base oil, and a lubricating oil composition which have low viscosity and a high viscosity index and are excellent in wear resistance and reduction in friction coefficient can be provided.

##STR00001##